The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Spyre Therapeutics's share price is $32.99.
Spyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.23. Hence, Spyre Therapeutics's PS Ratio for today is 141.59.
Warning Sign:
Spyre Therapeutics Inc stock PS Ratio (=267.27) is close to 10-year high of 267.27
The historical rank and industry rank for Spyre Therapeutics's PS Ratio or its related term are showing as below:
SYRE'
s PS Ratio Range Over the Past 10 Years
Min: 1.9 Med: 28.89 Max: 194.72
Current: 148.75
During the past 11 years, Spyre Therapeutics's highest PS Ratio was 194.72. The lowest was 1.90. And the median was 28.89.
SYRE's PS Ratio is ranked worse than 88.5% of 991
companies
in the Biotechnology industry
Industry Median: 8.98
vs SYRE: 148.75
Spyre Therapeutics's Revenue per Sharefor the
three
months ended in Dec. 2023 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.23.
During the past 12 months, the average Revenue per Share Growth Rate of Spyre Therapeutics was -81.50% per year.
During the past 11 years, Spyre Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 15.10% per year. The lowest was -29.50% per year. And the median was -7.20% per year.
Back to Basics: PS Ratio
Spyre Therapeutics PS Ratio Historical Data
The historical data trend for Spyre Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spyre Therapeutics's PS Ratio
For the Biotechnology subindustry, Spyre Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's PS Ratio falls into.
Spyre Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Spyre Therapeutics's PS Ratio for today is calculated as
Spyre Therapeutics's Share Price of today is $32.99.
Spyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Spyre Therapeutics (NAS:SYRE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Spyre Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Spyre Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Spyre Therapeutics (Spyre Therapeutics) Business Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SYRE has been successfully added to your 